Search Results52 results found
1 | STATEMENT ON SEASONAL INFLUENZA VACCINE FOR 2020-2021 An Advisory Committee Statement (ACS) National Advisory Committee
Abbreviation Term AE Adverse event AEFI Adverse event following immunization ART Antiretroviral therapy CAEFISS Canadian Adverse Events Following Immunization Surveillance System CI Confidence interval CIG Canadian Immunization Guide DIN Drug Identification Number FFU Fluorescent focus units GBS Guillain-Barré syndrome GMT Geometric mean titre GMTR Geometric mean titre ratio HA Hemagglutinin HAART Highly active antiretroviral therapy HCW Health care worker HIV Human immunodeficiency virus Ig Immunoglobulin IIV Inactivated influenza vaccine IIV3 Trivalent inactivated influenza vaccine IIV3-Adj Adjuvanted trivalent inactivated influenza vaccine (egg-based) IIV3-HD High-dose trivalent inactivated influenza vaccine (egg-based) IIV3-SD Standard-dose trivalent inactivated influenza vaccine (egg-based) IIV4 Quadrivalent inactivated influenza vaccine Mammalian cell culture-based quadrivalent inactivated influenza IIV4-cc vaccine IIV4-HD High-dose quadrivalent inactivated influenza vaccine (egg-based) IIV4-SD Standard-dose quadrivalent inactivated influenza vaccine (egg-based) ILI Influenza-like illness
Recommended composition of influenza virus vaccines for use in the 2022- 2023 northern hemisphere influenza season
and the Global Influenza Vaccine Effectiveness (GIVE) Collaboration for sharing estimates of influenza vaccine effectiveness on a confidential basis.
9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinin of influenza virus strains representing the influenza viruses likely to circulate in Canada in the upcoming winter on the basis of the recommendations from the World Health Organization (WHO) and the National Advisory Committee on Immunization (NACI).
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Amongamong Healthcare Personnel Aged 18-64 Years:
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
New Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake
Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults
Higher Dose and Adjuvanted Influenza Vaccines for Persons 65yr+